INTERACT4 Expansion - Validation Study

NCT07231315 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 465

Last updated 2025-11-19

No results posted yet for this study

Summary

As an investigator-initiated and conducted, multi-centre, open-label, single-arm prospective observational trial, INTERACT4 Expansion aims to evaluate the diagnostic accuracy of GFAP measured using a point-of-care device, for identifying ICH in participants presenting with acute stroke-like symptoms in the pre-hospital setting compared with imaging-confirmed ICH.

Conditions

  • Intracerebral Hemorrhage

Interventions

DIAGNOSTIC_TEST

LVOne

LVOne is an in vitro diagnostic rapid lateral flow chromatographic immunoassay kit

Sponsors & Collaborators

  • The George Institute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2026-11-01
Completion
2027-06-01

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07231315 on ClinicalTrials.gov